Development asset linked to XBiotech Germany in public FDA and regional records.
biotech · Rheumatoid Arthritis · Pharmacokinetics · XBIT
XBiotech Germany
XBiotech Germany GmbH
XBiotech Germany drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Baesweiler, DE HQ
30 Employees
Public company Type
XBIT · NYSE Ticker
Company details
- Status
- Public
- HQ
- Baesweiler, DE
- Employees
- 30
- Programs
- 8
- Drugs
- 6
- Patents
- 31
XBiotech Germany pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
XBiotech Germany drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to XBiotech Germany in public FDA and regional records.
-
human igg1 monoclonal antibody specific for human interleukin-1 alpha
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in XBiotech Germany's portfolio.
-
Development asset linked to XBiotech Germany in public FDA and regional records.
-
Development asset linked to XBiotech Germany in public FDA and regional records.
-
Development asset linked to XBiotech Germany in public FDA and regional records.